Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.

In 30 seconds

The phase 2, multicenter, randomized IZALCO study assessed patient-reported outcomes and healthcare provider experiences with subcutaneous isatuximab delivered by on-body injector (OBI) or manual injection, alongside carfilzomib-dexamethasone, in adults with relapsed/refractory multiple myeloma. In part 2, patients experienced both methods before stating a preference at cycle 6, day 15. Among 47 respondents, 74.5% (35/47) preferred OBI, citing comfort, convenience, and less injection-site pain. From cycle 7, 90.4% (47/52) chose OBI; most surveyed providers also preferred it.

Key findings

• After experiencing both methods, 74.5% (35/47) of patients preferred OBI at cycle 6, day 15.
• From cycle 7 onward, 90.4% (47/52) of patients opted for OBI.
• Fewer patients reported discomfort, pain, and side effects with OBI than manual injection at most time points.
• Among 19 providers, 78.9% (15/19) preferred OBI; mean EORTC QLQ-C30 global health status/quality-of-life score was maintained over time.

Why it matters

Administration experience can influence how patients and care teams view a treatment option. These findings indicate that, after trying both delivery methods, most surveyed patients and providers favored the on-body injector, with comfort, convenience, and injection-site pain among patients’ stated reasons. The maintained mean global health status/quality-of-life score provides additional patient-reported context, although it does not establish a comparative quality-of-life benefit.

What to keep in mind

Preference results were based on 47 patients at cycle 6, day 15, and the study assessed reported experiences rather than establishing a clinical advantage of one delivery method.